Zidesamtinib achieved a 44% ORR and 1% CR rate in advanced ROS1-positive NSCLC patients previously treated with ROS1 TKIs. The ARROS-1 trial showed zidesamtinib's efficacy, especially in patients with ...

Clinician and patient responses for cutaneous cGVHD were associated with higher nonrelapse mortality when comparing worsening vs improved disease.

A landmark clinical study identifies Human Papillomavirus (HPV) genotype as a significant independent predictor of treatment ...

MRI-guided personalisation of neoadjuvant chemotherapy duration is associated with improved 3-year survival outcomes in patients with stage II-III HER2-positive breast cancer, a new trial reports.

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25) 71% of patients with ...

Early and sustained clearance of circulating tumor DNA (ctDNA) was strongly associated with achieving pathologic complete response (pCR) in patients with early HER2-positive breast cancer receiving ...

CHICAGO and FORT WORTH, Texas, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on ...